CDK4 and breast carcinoma: In addition, strategies to maintain cancer cell dormancy, including estrogen antagonists, inhibition of CDK4/6, ERK, and integrin signaling, may prevent reactivation of dormant cancer cells and tumor relapse, as shown by an acceptable clinical response in breast cancer [60,130,131,132].